Recent meta-analyses including the finished major and many smaller cardiovascular safety studies for DPP-4 inhibitors have different conclusions, ranging from no increased risk for the hospitalization of heart failure after DPP4 inhibitor use [26] to an increased risk [27]. Here, DPP4 is linked to heart failure.